Oncotarget · 2021 · 10 citations · 32 references
MedicineCancer BiologyOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer GenomicsCancer ProgressionMalignant NeoplasmsMalignant TumorsPediatric Cancer GeneticsSquamous Cell CarcinomaCancer NeoantigensMetastatic Squamous Cell CarcinomaNeoantigen IdentificationNeoantigen RecognitionNeoplastic ProgressionPrimary Tumor CharacterizationPrimary Tumor ClassificationSquamous Cell Carcinoma Histopathology
// Charles R. Schutt 1 , * , Hua Sun 1 , 2 , * , Jaya Sarin Pradhan 3 , Yvonne Saenger 4 , Jessica Ley 1 , Douglas Adkins 1 , 7 , Matthew Ingham 4 , Li Ding 1 , 2 , 5 , 7 and Brian A. Van Tine 1 , 6 , 7 1 Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA 2 McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA 3 Department of Pathology and Cell Biology, Columbia University, New York, NY, USA 4 Division of Hematology/Oncology, Columbia University, New York, NY, USA 5 Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA 6 Division of Pediatric Hematology and Oncology, St. Louis Children’s Hospital, St. Louis, MO, USA 7 Siteman Cancer Center, St. Louis, MO, USA * Co-first authors Correspondence to: Brian A. Van Tine, email: bvantine@wustl.edu Keywords: head and neck squamous cell carcinoma; neoantigens; mutational evolution; tumor relapse; immune cell infiltration Abbreviations: ECM: Extracellular Matrix; HNSCC: Head and neck cell squamous-cell carcinomas; HPV: human papilloma virus; IHC: immunohistochemistry; WES: whole exome sequencing Received: February 02, 2021     Accepted: February 15, 2021     Published: March 16, 2021 Copyright: © 2021 Schutt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Head and neck cell squamous-cell carcinomas (HNSCC) are a group of common cancers typically associated with tobacco use and human papilloma virus infection. Up to half of all cases will suffer a recurrence after primary treatment. As such, new therapies are needed, including therapies which promote the anti-tumor immune response. Prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution. We characterized genomic and neoantigen changes between 23 paired primary and recurrent HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally advanced disease were identified from the Washington University tumor bank. Whole exosome sequencing, RNA-seq, and immunohistochemistry was performed on the primary and recurrent tumors. Within these tumors, we identified 6 genes which have predicted neoantigens in 4 or more patients. Interestingly, patients with neoantigens in these shared genes had increased CD3+ CD8+ T cell infiltration and duration of survival with disease. Within HNSCC tumors examined here, there are neoantigens in shared genes by a subset of patients. The presence of neoantigens in these shared genes may promote an anti-tumor immune response which controls tumor progression.
32
Near-optimal probabilistic RNA-seq quantification
Nicolas Bray, Harold Pimentel, Páll Melsted et al. · Nature Biotechnology · 2016 · 11K citations · Full text
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt, Qunyuan Zhang, David E. Larson et al. · Genome Research · 2012 · 5.3K citations · Full text
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney, Sachet A. Shukla, Catherine J. Wu et al. · Cell · 2015 · 4.1K citations · Full text
Medicine, Immunology, Oncology +17